Table 6. Relationship between EGFR and EZH2 expression and clinicopathological factors.

Clinical or pathological indicators	N	EGFR			EHZ2
		Relative expression	P value		Relative expression	P value
Age (years)			0.199			0.645
<40	21	0.537±0.280			0.582±0.346
40–59	71	0.715±0.263			0.526±0.324
≥60	28	0.604±0.266			0.429±0.201
Menopausal state			0.962			0.494
Not menopausal	65	0.651±0.280			0.478±0.290
Menopausal	55	0.675±0.257			0.574±0.317
T stage			0.623			0.217
T1	47	0.668±0.250			0.605±0.278
T2	64	0.670±0.297			0.492±0.335
T3	9	0.608±0.255			0.368±0.169
Lymph node			0.005*			0.024*
N0	40	0.473±0.282			0.344±0.279
N1	44	0.618±0.272			0.461±0.180
N2	20	0.750±0.096			0.552±0.140
N ≥3	16	0.865±0.099			0.721±0.313
Clinical stage			0.009*			0.013*
I	25	0.361±0.221			0.243±0.226
II	59	0.560±0.230			0.353±0.153
III	36	0.768±0.123			0.724±0.317
Pathological grade			0.405			0.154
I	15	0.816±0.040			0.769±0.371
II	75	0.674±0.254			0.422±0.210
III	30	0.592±0.318			0.610±0.373
Ki-67			0.203			0.046*
<20%	36	0.566±0.257			0.380±0.269
20–30%	32	0.661±0.297			0.516±0.310
>30%	52	0.751±0.242			0.638±0.283
P53			0.770			0.538
+	79	0.635±0.330			0.476±0.243
−	41	0.574±0.334			0.419±0.327

*, indicates the result is statistically significant. EGFR, epidermal growth factor receptor; EZH2, zeste gene enhancer homolog 2.